{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T14:57:04Z","timestamp":1772117824920,"version":"3.50.1"},"update-to":[{"DOI":"10.1002\/14651858.cd008946","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2012,9,12]],"date-time":"2012-09-12T00:00:00Z","timestamp":1347408000000}}],"reference-count":116,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd008946.pub2","type":"journal-article","created":{"date-parts":[[2012,9,4]],"date-time":"2012-09-04T18:37:38Z","timestamp":1346783858000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Interventions for mycosis fungoides"],"prefix":"10.1002","author":[{"given":"Tobias","family":"Weberschock","sequence":"first","affiliation":[{"name":"Goethe University; Evidence-Based Medicine Frankfurt, Institute of General Practice; Theodor Stern Kai 7 Frankfurt Germany 60590"},{"name":"J.W. Goethe-University Hospital; Department of Dermatology, Venereology, and Allergology; Theodor-Stern-Kai 7 Frankfurt Germany 60590"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reinhard","family":"Strametz","sequence":"additional","affiliation":[{"name":"Goethe University; Evidence-Based Medicine Frankfurt, Institute of General Practice; Theodor Stern Kai 7 Frankfurt Germany 60590"},{"name":"Hochschule RheinMain University of Applied Science; Wiesbaden Business School; Wiesbaden Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Lorenz","sequence":"additional","affiliation":[{"name":"Faculty of Medicine Carl Gustav Carus, TU Dresden; Institute and Outpatient Clinics of Occupational and Social Medicine; Fetscherstr. 74 Dresden Germany 01307"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"R\u00f6llig","sequence":"additional","affiliation":[{"name":"University Hospital Carl Gustav Carus; Medical Department I; Fetscherstra\u00e2e 74 Dresden Germany 01307"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Bunch","sequence":"additional","affiliation":[{"name":"The University of Nottingham; c\/o Cochrane Skin Group; A103, King's Meadow Campus Lenton Lane Nottingham UK Ng7 1NR"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Bauer","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinikum Carl Gustav Carus; Department of Dermatology; Fetscherstr. 74 Dresden Germany 01307"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jochen","family":"Schmitt","sequence":"additional","affiliation":[{"name":"Faculty of Medicine Carl Gustav Carus, Technischen Universit\u00e4t (TU) Dresden; Center for Evidence-Based Healthcare; Fetscherstr. 74 Dresden Germany 01307"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,9,12]]},"reference":[{"issue":"3","key":"10.1002\/14651858.CD008946.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1365-2230.2004.01525.x","article-title":"A randomized cross-over study to compare PUVA and extracorporeal photopheresis in the treatment of plaque stage (T2) mycosis fungoides","volume":"29","author":"Child","year":"2004","journal-title":"Clinical & Experimental Dermatology"},{"issue":"Suppl 59","key":"10.1002\/14651858.CD008946.pub2-BIB0002|cit2","first-page":"16","article-title":"A randomised cross-over study to compare Puva and extracorporeal photopheresis (ECP) in the treatment of plaque stage (T2) mycosis fungoides","volume":"145","author":"Child","year":"2001","journal-title":"British Journal of Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD008946.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1080\/09546630310019373","article-title":"Imiquimod 5% cream in the treatment of mycosis fungoides - a pilot study","volume":"15","author":"Chong","year":"2004","journal-title":"Journal of Dermatological Treatment"},{"issue":"5","key":"10.1002\/14651858.CD008946.pub2-BIB0004|cit4","first-page":"581","article-title":"Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma","volume":"137","author":"Duvic","year":"2001","journal-title":"Archives of Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD008946.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1046\/j.1440-0960.2001.00488.x","article-title":"Bexarotene capsules and gel for previously treated patients with cutaneous T-cell lymphoma: results of the Australian patients treated on phase II trials","volume":"42","author":"Prince","year":"2001","journal-title":"Australasian Journal of Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD008946.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1067\/mjd.2001.113478","article-title":"A phase III, randomized, double-blind, placebo-controlled study of peldesine (BCX-34) cream as topical therapy for cutaneous T-cell lymphoma","volume":"44","author":"Duvic","year":"2001","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD008946.pub2-BIB0007|cit7","first-page":"241","article-title":"Low Dose Bexarotene (Targretin\u00ae) Capsules and Phototherapy for Early Stage Cutaneous T-Cell Lymphoma. [Abstract 199]. The 63rd Annual Meeting of the Society for Investigative Dermatology, 15-18 May, Los Angeles, USA","volume":"119","author":"Guitart","year":"2002","journal-title":"Journal of Investigative Dermatology"},{"key":"10.1002\/14651858.CD008946.pub2-BIB0008|cit8","unstructured":"NCT00030589 A Muliticenter, Dose-Reandomized Evaluation Of Targretin Capsules Plus PUVA In Patients With Stage IB - IIA Cutaneous T-Cell Lymphoma clinicaltrials.gov\/ct\/show\/NCT00030589"},{"key":"10.1002\/14651858.CD008946.pub2-BIB0009|cit9","first-page":"257","article-title":"Conservative vs. aggressive therapy in mycosis fungoides [Abstract 1002]","volume":"8","author":"Kaye","year":"1989","journal-title":"Proceedings of the American Society of Clinical Oncology"},{"key":"10.1002\/14651858.CD008946.pub2-BIB0010|cit10","first-page":"195","article-title":"A randomized trial comparing conservative and aggressive therapy in mycosis fungoides (MF) [Abstract 765]","volume":"5","author":"Kaye","year":"1986","journal-title":"Proceedings of the American Society of Clinical Oncology"},{"issue":"26","key":"10.1002\/14651858.CD008946.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1056\/NEJM198912283212603","article-title":"A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides","volume":"321","author":"Kaye","year":"1989","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD008946.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"222","DOI":"10.3816\/CLM.2002.n.003","article-title":"Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK)","volume":"2","author":"Duvic","year":"2002","journal-title":"Clinical Lymphoma"},{"issue":"10 Suppl 1 (Pt","key":"10.1002\/14651858.CD008946.pub2-BIB0013|cit13","first-page":"586a","article-title":"Pivotal phase III trial of two dose levels of DAB389IL-2 (Ontak\u00ae) for the treatment of mycosis fungoides (MF)","volume":"90","author":"Kuzel","year":"1997","journal-title":"Blood"},{"key":"10.1002\/14651858.CD008946.pub2-BIB0014|cit14","unstructured":"NTC00050999 Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients clinicaltrials.gov\/ct2\/show\/NCT00050999"},{"issue":"2","key":"10.1002\/14651858.CD008946.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1200\/JCO.2001.19.2.376","article-title":"Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma","volume":"19","author":"Olsen","year":"2001","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10.1002\/14651858.CD008946.pub2-BIB0016|cit16","first-page":"678","article-title":"Pivotal phase III trial of two dose levels of DAB 389 IL-2 (ONTAK) for the treatment of cutaneous T-cell lymphoma (CTCL) [Abstract 1234]","volume":"110","author":"Olsen","year":"1998","journal-title":"Journal of Investigative Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD008946.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.jaad.2010.02.039","article-title":"A phase II placebo-controlled study of photodynamic therapy with topical hypericin and visible light irradiation in the treatment of cutaneous T-cell lymphoma and psoriasis","volume":"63","author":"Rook","year":"2010","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"Suppl","key":"10.1002\/14651858.CD008946.pub2-BIB0018|cit18","first-page":"S97","article-title":"Treatment of cutaneous T-cell lymphoma with Interferon alpha and PUVA versus Interferon alpha and Acitretin - results of a prospective randomised multi-centre study","volume":"48","author":"Otte","year":"1997","journal-title":"Der Hautarzt"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD008946.pub2-BIB0019|cit19","first-page":"66","article-title":"Open controlled clinical trial on the use of interferon plus acitretin versus interferon plus PUVA in patients with cutaneous T-cell lymphoma (CTCL) [Poster P232]","volume":"7","author":"Otte","year":"1996","journal-title":"Annals of Oncology"},{"issue":"10","key":"10.1002\/14651858.CD008946.pub2-BIB0020|cit20","first-page":"3578","article-title":"Prospective randomized multicenter clinical trial on the use of interferon -2a plus acitretin versus interferon -2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II","volume":"92","author":"Stadler","year":"1998","journal-title":"Blood"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD008946.pub2-BIB0021|cit21","first-page":"S268","article-title":"Therapy of cutaneous T-cell lymphoma with PUVA versus interferon alfa plus PUVA: first results [Abstract P-447]","volume":"12","author":"Bohmeyer","year":"1999","journal-title":"Journal of the European Academy of Dermatology & Venereology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008946.pub2-BIB0022|cit22","first-page":"S55","article-title":"Prospective randomized multicentre therapy optimizing protocol for therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon \u03b1 + PUVA","volume":"76","author":"Bohmeyer","year":"2001","journal-title":"Zeitschrift f\u00fcr Hautkrankheiten"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008946.pub2-BIB0023|cit23","first-page":"S99","article-title":"Prospective randomized multicentre therapy optimizing protocol for therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon \u03b1 + PUVA","volume":"1","author":"Kremer","year":"2003","journal-title":"Journal der Deutschen Dermatologischen Gesellschaft"},{"issue":"Suppl","key":"10.1002\/14651858.CD008946.pub2-BIB0025|cit24","first-page":"P2.03.08","article-title":"combination therapy of cutaneous t-cell-lymphoma with interferon alfa 2a and PUVA","volume":"162","author":"Otte","year":"1993","journal-title":"Zentralblatt Haut- und Geschlechtskrankheiten"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008946.pub2-BIB0024|cit25","first-page":"S2","article-title":"Therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon \u03b1 plus PUVA: first results of a prospective randomized multicentre therapy optimizing protocol","volume":"50","author":"Otte","year":"1999","journal-title":"Der Hautarzt"},{"issue":"18S Pt 1","key":"10.1002\/14651858.CD008946.pub2-BIB0026|cit26","first-page":"432","article-title":"Prospective, randomized, multicentre clinical trial on the use of interferon a 2a plus PUVA versus PUVA monotherapy in patients with cutaneous T-cell lymphoma, stages I and II [Abstract 7541]. ASCO annual meeting proceedings","volume":"24","author":"Stadler","year":"2006","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD008946.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2340\/00015555624753","article-title":"Transfer factor therapy in mycosis fungoides: a double-blind study","volume":"62","author":"Thestrup-Pedersen","year":"1982","journal-title":"Acta Dermato-Venereologica"},{"issue":"6","key":"10.1002\/14651858.CD008946.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1001\/archderm.1987.01660300079016","article-title":"Recombinant interferon alfa-2b in plaque-phase mycosis fungoides. Intralesional and low-dose intramuscular therapy","volume":"123","author":"Vonderheid","year":"1987","journal-title":"Archives of Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD008946.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/S0190-9622(85)70205-8","article-title":"Intralesional interferon in the treatment of early mycosis fungoides","volume":"13","author":"Wolff","year":"1985","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD008946.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1365-2133.2008.08886.x","article-title":"Psoralen plus ultraviolet A +\/- interferon-alpha treatment resistance in mycosis fungoides: the role of tumour microenvironment, nuclear transcription factor-kappaB and T-cell receptor pathways","volume":"160","author":"Wozniak","year":"2008","journal-title":"British Journal of Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD008946.pub2-BIB0031|cit31","first-page":"619","article-title":"Preliminary evaluation of 15 chemotherapeutic agents applied topically in the treatment of mycosis fungoides","volume":"63","author":"Argyropoulos","year":"1979","journal-title":"Cancer Treatment Reports"},{"issue":"6 Pt 1","key":"10.1002\/14651858.CD008946.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/0190-9622(91)70307-N","article-title":"Topical mechlorethamine in the treatment of mycosis fungoides. Uniformity of application and potential for environmental contamination","volume":"25","author":"Breneman","year":"1991","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD008946.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1200\/JCO.1994.12.4.769","article-title":"Randomized comparison of MACOP-B with CHOP in patients with intermediate-grade non-Hodgkin's lymphoma. The Australian and New Zealand Lymphoma Group","volume":"12","author":"Cooper","year":"1994","journal-title":"Journal of Clinical Oncology"},{"issue":"8-9","key":"10.1002\/14651858.CD008946.pub2-BIB0034|cit34","first-page":"951","article-title":"Phase I trial of metoprine in patients with advanced cancer","volume":"64","author":"Currie","year":"1980","journal-title":"Cancer Treatment Reports"},{"issue":"3","key":"10.1002\/14651858.CD008946.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1365-2141.2006.06457.x","article-title":"Phase II Study of Denileukin Diftitox for Relapsed\/Refractory B-Cell Non-Hodgkin's Lymphoma","volume":"136","author":"Dang","year":"2007","journal-title":"British Journal of Haematology"},{"issue":"3","key":"10.1002\/14651858.CD008946.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1111\/j.1749-6632.1958.tb42654.x","article-title":"Clinical evaluation of CB 1348 in leukemias and lymphomas","volume":"68","author":"Doan","year":"1958","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"19","key":"10.1002\/14651858.CD008946.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1002\/cncr.25377","article-title":"Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma","volume":"116","author":"Dueck","year":"2010","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD008946.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.1097\/01.cmr.0000382933.41435.dc","article-title":"Broadband UVA versus PUVA in the treatment of early stage mycosis fungoides: A comparative study. [Abstract P99]. 6th Congress of the European Association of Dermatologic Oncology Athens Greece. 16-19 June 2010","volume":"20","author":"Fawzi","year":"2010","journal-title":"Melanoma Research"},{"issue":"14","key":"10.1002\/14651858.CD008946.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJM199304083281404","article-title":"Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma","volume":"328","author":"Fisher","year":"1993","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD008946.pub2-BIB0040|cit40","unstructured":"JapicCTI-050041 Post-marketing clinical study of Ogamma 100 in patients with mycosis fungoides www.clinicaltrials.jp\/user\/showCteDetailE.jsp?japicId=JapicCTI-050041"},{"issue":"6","key":"10.1002\/14651858.CD008946.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1002\/1097-0142(196906)23:6<1280::AID-CNCR2820230606>3.0.CO;2-U","article-title":"Comparison of chlorambucil and streptonigrin (NSC-45383) in the treatment of malignant lymphomas","volume":"23","author":"Kaung","year":"1969","journal-title":"Cancer"},{"issue":"1","key":"10.1002\/14651858.CD008946.pub2-BIB0042|cit42","article-title":"PUVA vs. PUVA and interferon alpha for treatment of mycosis fungoides. [Abstract 1185]. International Investigative Dermatology. The 4th Joint Meeting of the ESDR, Japanese SID & SID, 30th April-4thMay 2003, Florida, USA","volume":"121","author":"Kujawska","year":"2003","journal-title":"Journal of Investigative Dermatology"},{"issue":"15 Suppl May","key":"10.1002\/14651858.CD008946.pub2-BIB0043|cit43","article-title":"Correlates of capillary leak syndrome (CLS) in patients with cutaneous T-cell lymphoma (CTCL) during treatment with denileukin diftitox (DD) in a placebo (PBO)-controlled phase III trial. [Abstract e18509 ]. 4-8 June 2010 Annual Meeting of the American Society of Clinical Oncology, ASCO Chicago, IL United States","volume":"28","author":"Kuzel","year":"2010","journal-title":"Journal of Clinical Oncology"},{"issue":"15 Suppl May","key":"10.1002\/14651858.CD008946.pub2-BIB0044|cit44","article-title":"Rate of infection and immunosuppression in two phase III studies of denileukin diftitox (DD) in cutaneous T-cell lymphoma (CTCL). [Abstract e18515]. 4-8 June 2010 Annual Meeting of the American Society of Clinical Oncology, ASCO Chicago, IL United States","volume":"28","author":"Lansigan","year":"2010","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD008946.pub2-BIB0045|cit45","unstructured":"NCT00054171 Phase I Randomized Pilot Study of Photodynamic Therapy Using Aminolevulinic Acid in Patients With Cutaneous T-Cell or B-Cell Lymphoma or Early Chronic Lymphocytic Leukemia With Cutaneous Infiltrates clinicaltrials.gov\/ct\/show\/NCT00054171"},{"issue":"6","key":"10.1002\/14651858.CD008946.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1159\/000252071","article-title":"Treatment of localized skin lesions with betamethasone 17-valerate and triamcinolone acetonide in alcoholic solution under occlusive dressing. A double blind comparative study","volume":"145","author":"Neering","year":"1972","journal-title":"Dermatologica"},{"issue":"18S Suppl June","key":"10.1002\/14651858.CD008946.pub2-BIB0047|cit47","first-page":"447","article-title":"Efficacy and safety of denileukin diftitox (Dd) in a phase III, double-blind, placebo-controlled study of CD25+ patients with cutaneous T-cell lymphoma (CTCL) [Abstract 8026]. ASCO annual meeting proceedings","volume":"25","author":"Negro-Vilar","year":"2007","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD008946.pub2-BIB0048|cit48","first-page":"49","article-title":"Comparison of the use of teniposide and vincristine in combination chemotherapy for non-Hodgkin's lymphoma","volume":"66","author":"No authors","year":"1982","journal-title":"Cancer Treatment Reports"},{"key":"10.1002\/14651858.CD008946.pub2-BIB0049|cit49","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1111\/1523-1747.ep12285810","article-title":"Interferon alfa-2A in the treatment of cutaneous T cell lymphoma [Abstract]. 47th Annual Meeting of The Society for Investigative Dermatology, Inc, Washington, D.C. 1-4 May 1986","volume":"4","author":"Olsen","journal-title":"Journal of Investigative Dermatology"},{"key":"10.1002\/14651858.CD008946.pub2-BIB0050|cit50","doi-asserted-by":"crossref","unstructured":"Pan Y Prince HM Ellis L Culver K LBH589, a Novel Deacetylase Inhibitor (DACi), in the Treatment of Cutaneous T-Cell Lymphoma (CTCL): Changes in tumor Gene Expression Profiles Related to Clinical Response after Therapy. [Abstract 00172] The 11th World Congress on Cancers of the Skin. Amsterdam, The Netherlands. 8th-11th June 2007 2007","DOI":"10.1182\/blood.V108.11.2715.2715"},{"issue":"4","key":"10.1002\/14651858.CD008946.pub2-BIB0051|cit51","first-page":"563","article-title":"Clinical efficacy of a novel purine nucleoside phosphorylase inhibitor (BCX-34) in the treatment of cutaneous T-cell lymphoma. [Abstract 54]. 1995 Annual Meeting of the Society for Investigative Dermatology","volume":"104","author":"Peugeot","year":"1995","journal-title":"Journal of Investigative Dermatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008946.pub2-BIB0052|cit52","first-page":"S96","article-title":"UVA1-Phototherapie versus PUVA-Photochemotherapie in der Behandlung von Patienten mit kutanem T-Zell-Lymphom (CTCL)","volume":"76","author":"Plettenberg","year":"2001","journal-title":"Zeitschrift f\u00fcr Hautkrankheiten"},{"issue":"11","key":"10.1002\/14651858.CD008946.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1200\/JCO.2009.26.2386","article-title":"Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma","volume":"28","author":"Prince","year":"2010","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl","key":"10.1002\/14651858.CD008946.pub2-BIB0054|cit54","first-page":"S96","article-title":"Extracorporal photophoresis (ECP) + Interferon-alpha 2a vs. ECP in patients with cutaneous T-cell lymphoma. Evaluation using a new score (CTCL-SI) (German)","volume":"48","author":"Schrag","year":"1997","journal-title":"Der Hautarzt"},{"issue":"2","key":"10.1002\/14651858.CD008946.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1365-2141.2010.08329.x","article-title":"Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP\/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95","volume":"151","author":"Simon","year":"2010","journal-title":"British Journal of Haematology"},{"issue":"2","key":"10.1002\/14651858.CD008946.pub2-BIB0056|cit56","first-page":"287","article-title":"Scandinavian mycosis fungoides study group","volume":"64","author":"Thomsen","year":"1977","journal-title":"Bulletin du Cancer"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008946.pub2-BIB0057|cit57","first-page":"10","article-title":"A randomized, open, crossover study to compare the efficacy of extracorporeal photopheresis with methotrexate in the treatment of erythrodermic primary cutaneous T-cell lymphoma. [Abstract RF-5]. The 85th BAD Annual Meeting 5-8th July 2005, Glasgow, UK","volume":"153","author":"Wain","year":"2005","journal-title":"British Journal of Dermatology"},{"issue":"5-6","key":"10.1002\/14651858.CD008946.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"601","DOI":"10.3109\/10428199809057572","article-title":"Phase II study of mitoguazone, cyclophosphamide, doxorubicin, vincristine and prednisone for patients with diffuse histologic subtypes of non-Hodgkin's lymphoma: an Eastern Cooperative Oncology Group Study (PE481)","volume":"30","author":"Wiernik","year":"1998","journal-title":"Leukemia & Lymphoma"},{"issue":"1","key":"10.1002\/14651858.CD008946.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/0021-9681(60)90137-5","article-title":"Appraisal of methods for the study of chemotherapy of cancer in man: Comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramide","volume":"11","author":"Zubrod","year":"1960","journal-title":"Journal of Chronic Diseases"},{"issue":"7","key":"10.1002\/14651858.CD008946.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/ajh.22039","article-title":"Predictors of complete responses with denileukin diftitox in cutaneous T-cell lymphoma","volume":"86","author":"Foss","year":"2011","journal-title":"American Journal of Hematology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008946.pub2-BIB0061|cit61","first-page":"S84","article-title":"Positive results of a pivotal phase ii trial testing a manufactured 0.02% Mechlorethamine gel in mycosis fungoides (mf) [Abstract 503]. Annual Meeting of the Society for Investigative Dermatology Phoenix, AZ United States, 4-7 May 2011","volume":"131","author":"Lessin","year":"2011","journal-title":"Journal of Investigative Dermatology"},{"key":"10.1002\/14651858.CD008946.pub2-BIB0062|cit62","unstructured":"NCT00056056 Phase III Randomized Study of Ultraviolet A Light Therapy With Methoxsalen (PUVA) With or Without Bexarotene in Patients With Mycosis Fungoides clinicaltrials.gov\/ct\/show\/NCT00056056"},{"key":"10.1002\/14651858.CD008946.pub2-BIB0063|cit63","unstructured":"NCT00091208 A Phase I\/II Open Label, Multi-Center Study For The Evaluation Of CPG 7909 In Patients With Stage IB To IVA Cutaneous T-Cell Lymphoma clinicaltrials.gov\/ct\/show\/NCT00091208"},{"key":"10.1002\/14651858.CD008946.pub2-BIB0064|cit64","unstructured":"NCT00168064 A Phase II Pivotal Trial to Evaluate the Safety and Efficacy of Nitrogen Mustard (NM) 0.02% Ointment Formulations in Patients With Stage I or IIA Mycosis Fungoides (MF) clinicaltrials.gov\/ct\/show\/NCT000168064"},{"key":"10.1002\/14651858.CD008946.pub2-BIB0065|cit65","unstructured":"NCT01007448 Phase IV Randomized Study Of Two Dose Levels Of Targretin Capsules In Patients With Refractory Cutaneous T-Cell Lymphoma clinicaltrials.gov\/ct\/show\/NCT01007448"},{"key":"10.1002\/14651858.CD008946.pub2-BIB0066|cit66","unstructured":"NCT01098656 A Phase III Study of Lenalidomide Maintenance After Debulking With Gemcitabine or Liposomal Doxorubicin +\/- Radiotherapy in Patients With Advanced Cutaneous T-Cell Lymphoma Not Previously Treated With Intravenous Chemotherapy clinicaltrials.gov\/ct\/show\/NCT01098656"},{"key":"10.1002\/14651858.CD008946.pub2-BIB0067|cit67","unstructured":"NCT01187446 A Multicenter, Open-label, Randomized, Phase I\/II Study Evaluating the Safety and Efficacy of Low-dose (12 Gy) Total Skin Electron Beam Therapy (TSEBT) Combined With Vorinostat Versus Low-dose TSEBT Monotherapy in Mycosis Fungoides (MF) clinicaltrials.gov\/ct\/show\/NCT01187446"},{"key":"10.1002\/14651858.CD008946.pub2-BIB0068|cit68","unstructured":"NCT01386398 Vorinostat (Zolinza\u00ae) in Combination With (Velcade\u00ae) Versus Vorinostat Alone in Refractory or Recurrent Advanced CTCL: A Randomized Phase III Study clinicaltrials.gov\/ct\/show\/NCT01386398"},{"key":"10.1002\/14651858.CD008946.pub2-BIB0069|cit69","unstructured":"NCT01433731 A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Phase 1b Study to Assessthe Safety, Pharmacodynamics and Pharmacokinetics of SHP 141, A Histone DeacetylaseInhibitor, Administered Topically Up to 28 Days to Patients With Stage IA, IB or IIA CutaneousT-Cell Lymphoma clinicaltrials.gov\/ct\/show\/NCT01433731"},{"issue":"31","key":"10.1002\/14651858.CD008946.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"4730","DOI":"10.1200\/JCO.2009.27.7665","article-title":"Survival outcomes and prognostic factors in mycosis fungoides\/Sezary syndrome: validation of the revised International Society for Cutaneous Lymphomas\/European Organisation for Research and Treatment of Cancer staging proposal","volume":"28","author":"Agar","year":"2010","journal-title":"Journal of Clinical Oncology"},{"issue":"13","key":"10.1002\/14651858.CD008946.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1001\/jama.1989.03420130044019","article-title":"Mycosis fungoides","volume":"261","author":"Bernstein","year":"1989","journal-title":"JAMA"},{"issue":"21","key":"10.1002\/14651858.CD008946.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1182\/blood-2008-10-184168","article-title":"Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases","volume":"113","author":"Bradford","year":"2009","journal-title":"Blood"},{"issue":"4","key":"10.1002\/14651858.CD008946.pub2-BIB0073|cit73","first-page":"725","article-title":"Report of the committee on staging and classification of cutaneous T-cell lymphomas","volume":"63","author":"Bunn","year":"1979","journal-title":"Cancer Treatment Reports"},{"issue":"3","key":"10.1002\/14651858.CD008946.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1200\/JCO.1993.11.3.570","article-title":"The Functional Assessment of Cancer Therapy scale: development and validation of the general measure","volume":"11","author":"Cella","year":"1993","journal-title":"Journal of Clinical Oncology"},{"issue":"20","key":"10.1002\/14651858.CD008946.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1001\/jama.291.20.2457","article-title":"Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles","volume":"291","author":"Chan","year":"2004","journal-title":"JAMA"},{"issue":"7","key":"10.1002\/14651858.CD008946.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1001\/archderm.143.7.854","article-title":"Incidence of cutaneous T-cell lymphoma in the United States, 1973-2002","volume":"143","author":"Criscione","year":"2007","journal-title":"Archives of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD008946.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/ije\/dyp174","article-title":"How to assess the external validity of therapeutic trials: a conceptual approach","volume":"39","author":"Dekkers","year":"2010","journal-title":"International Journal of Epidemiology"},{"issue":"6964","key":"10.1002\/14651858.CD008946.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1136\/bmj.309.6964.1286","article-title":"Identifying relevant studies for systematic reviews","volume":"309","author":"Dickersin","year":"1994","journal-title":"BMJ"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD008946.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"ii72","DOI":"10.1093\/annonc\/mdn095","article-title":"Primary cutaneous lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up","volume":"19","author":"Dummer","year":"2008","journal-title":"Annals of Oncology"},{"issue":"6","key":"10.1002\/14651858.CD008946.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"478","DOI":"10.7861\/clinmedicine.1-6-478","article-title":"Uses and abuses of meta-analysis","volume":"1","author":"Egger","year":"2001","journal-title":"Clinical Medicine"},{"issue":"2","key":"10.1002\/14651858.CD008946.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/CCO.0b013e3283253190","article-title":"Update on treatment of cutaneous T-cell lymphoma","volume":"21","author":"Gardner","year":"2009","journal-title":"Current Opinion in Oncology"},{"issue":"4","key":"10.1002\/14651858.CD008946.pub2-BIB0082|cit82","first-page":"48","article-title":"Biotech Baddies","volume":"23","author":"Grant","year":"2009","journal-title":"The Scientist"},{"issue":"13","key":"10.1002\/14651858.CD008946.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1001\/jama.1983.03330370053031","article-title":"If nothing goes wrong, is everything all right? Interpreting zero numerators","volume":"249","author":"Hanley","year":"1983","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD008946.pub2-BIB0084|cit84","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"7211","key":"10.1002\/14651858.CD008946.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1136\/bmj.319.7211.670","article-title":"What is meant by intention to treat analysis? Survey of published randomised controlled trials","volume":"319","author":"Hollis","year":"1999","journal-title":"BMJ"},{"issue":"9616","key":"10.1002\/14651858.CD008946.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/S0140-6736(08)60420-1","article-title":"Mycosis fungoides and S\u00e9zary syndrome","volume":"371","author":"Hwang","year":"2008","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD008946.pub2-BIB0087|cit87","volume-title":"Pathology and Genetics: Tumours of Hematopoetic and Lymphoid Tissues (World Health Organization Classification of Tumours)","author":"Jaffe","year":"2001"},{"issue":"7303","key":"10.1002\/14651858.CD008946.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1136\/bmj.323.7303.42","article-title":"Systematic reviews in health care: Assessing the quality of controlled clinical trials","volume":"323","author":"J\u00fcni","year":"2001","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD008946.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1093\/ije\/31.1.115","article-title":"Direction and impact of language bias in meta-analyses of controlled trials: Empirical study","volume":"31","author":"J\u00fcni","year":"2002","journal-title":"International Journal of Epidemiology"},{"issue":"11","key":"10.1002\/14651858.CD008946.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1001\/archderm.1996.03890350051009","article-title":"Clinical stage IA (limited patch and plaque) mycosis fungoides. A long-term outcome analysis","volume":"132","author":"Kim","year":"1996","journal-title":"Archives of Dermatology"},{"issue":"7","key":"10.1002\/14651858.CD008946.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1001\/archderm.139.7.857","article-title":"Long-term outcome of 525 patients with mycosis fungoides and S\u00e9zary syndrome: Clinical prognostic factors and risk for disease progression","volume":"139","author":"Kim","year":"2003","journal-title":"Archives of Dermatology"},{"issue":"9005","key":"10.1002\/14651858.CD008946.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S0140-6736(96)91350-1","article-title":"Cutaneous T-cell lymphoma (mycosis fungoides)","volume":"347","author":"Lorincz","year":"1996","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD008946.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/sim.4780040211","article-title":"Comparative analysis of two rates","volume":"4","author":"Miettinen","year":"1985","journal-title":"Statistics in medicine"},{"issue":"1","key":"10.1002\/14651858.CD008946.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/0197-2456(94)00031-W","article-title":"Assessing the quality of randomized controlled trials: An annotated bibliography of scales and checklists","volume":"16","author":"Moher","year":"1995","journal-title":"Controlled Clinical Trials"},{"issue":"10","key":"10.1002\/14651858.CD008946.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"62","author":"Moher","year":"2009","journal-title":"Journal of Clinical Epidemiology"},{"issue":"1","key":"10.1002\/14651858.CD008946.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"64","DOI":"10.2340\/00015555596468","article-title":"Mycosis fungoides plaque stage treated with topical nitrogen mustard with and without attempts at tolerance induction: report from the Scandinavian mycosis fungoides study group","volume":"59","author":"Molin","year":"1979","journal-title":"Acta Dermato-Venereologica"},{"issue":"1","key":"10.1002\/14651858.CD008946.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1159\/000018423","article-title":"Mycosis fungoides: Review of epidemiological observations","volume":"201","author":"Morales Su\u00e1rez-Varela","year":"2000","journal-title":"Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD008946.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood-2007-03-055749","article-title":"Revisions to the staging and classification of mycosis fungoides and S\u00e9zary syndrome: A proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)","volume":"110","author":"Olsen","year":"2007","journal-title":"Blood"},{"issue":"18","key":"10.1002\/14651858.CD008946.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1200\/JCO.2010.32.0630","article-title":"Clinical end points and response criteria in mycosis fungoides and Sezary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer","volume":"29","author":"Olsen","year":"2011","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"10.1002\/14651858.CD008946.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"372","DOI":"10.7326\/0003-4819-109-5-372","article-title":"Histopathologic staging at initial diagnosis of mycosis fungoides and the S\u00e9zary syndrome. Definition of three distinctive prognostic groups","volume":"109","author":"Sausville","year":"1988","journal-title":"Annals of Internal Medicine"},{"issue":"1","key":"10.1002\/14651858.CD008946.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/1097-0142(19800101)45:1<137::AID-CNCR2820450124>3.0.CO;2-K","article-title":"Dermatopathic lymphadenopathy and lymph node involvement in mycosis fungoides","volume":"45","author":"Scheffer","year":"1980","journal-title":"Cancer"},{"issue":"1","key":"10.1002\/14651858.CD008946.pub2-BIB0102|cit102","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008908.pub2","article-title":"Allogeneic stem cell transplantation versus conventional therapy for advanced primary cutaneous T-cell lymphoma","author":"Schlaak","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"12","key":"10.1002\/14651858.CD008946.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/0021-9681(81)90058-8","article-title":"Measuring the quality of life of cancer patients: a concise QL-index for use by physicians","volume":"34","author":"Spitzer","year":"1981","journal-title":"Journal of Chronic Diseases"},{"issue":"8","key":"10.1002\/14651858.CD008946.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.ejca.2006.01.025","article-title":"EORTC consensus recommendations for the treatment of mycosis fungoides\/S\u00e9zary syndrome","volume":"42","author":"Trautinger","year":"2006","journal-title":"European Journal of Cancer"},{"issue":"4","key":"10.1002\/14651858.CD008946.pub2-BIB0105|cit105","first-page":"504","article-title":"Mycosis fungoides: Disease evolution and prognosis of 309 Dutch patients","volume":"136","author":"Doorn","year":"2000","journal-title":"Archives of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD008946.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/1097-0142(197307)32:1<18::AID-CNCR2820320103>3.0.CO;2-Q","article-title":"Complete remissions of mycosis fungoides lymphoma induced by topical nitrogen mustard (HN2). Control of delayed hypersensitivity to HN2 by desensitization and by induction of specific immunologic tolerance","volume":"32","author":"Scott","year":"1973","journal-title":"Cancer"},{"issue":"12","key":"10.1002\/14651858.CD008946.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/S0895-4356(98)00131-0","article-title":"The Delphi list: A criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus","volume":"51","author":"Verhagen","year":"1998","journal-title":"Journal of Clinical Epidemiology"},{"issue":"9","key":"10.1002\/14651858.CD008946.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1080\/10428190600709655","article-title":"S\u00e9zary cell counts in erythrodermic cutaneous T-cell lymphoma: Implications for prognosis and staging","volume":"47","author":"Vonderheid","year":"2006","journal-title":"Leukemia & Lymphoma"},{"issue":"10","key":"10.1002\/14651858.CD008946.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1002\/cncr.11780","article-title":"Outcome in 34 patients with juvenile-onset mycosis fungoides: A clinical, immunophenotypic, and molecular study","volume":"98","author":"Wain","year":"2003","journal-title":"Cancer"},{"issue":"1","key":"10.1002\/14651858.CD008946.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1001\/jama.1988.03410010050033","article-title":"Mycosis fungoides in the United States. Increasing incidence and descriptive epidemiology","volume":"260","author":"Weinstock","year":"1988","journal-title":"JAMA"},{"issue":"1","key":"10.1002\/14651858.CD008946.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/(SICI)1097-0142(19990101)85:1<208::AID-CNCR28>3.0.CO;2-2","article-title":"The changing survival of patients with mycosis fungoides: A population-based assessment of trends in the United States","volume":"85","author":"Weinstock","year":"1999","journal-title":"Cancer"},{"issue":"6","key":"10.1002\/14651858.CD008946.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1111\/j.1365-2133.2003.05698.x","article-title":"Joint British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous T-cell lymphomas","volume":"149","author":"Whittaker","year":"2003","journal-title":"British Journal of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD008946.pub2-BIB0113|cit113","first-page":"354","article-title":"EORTC classification for primary cutaneous lymphomas: A proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer","volume":"90","author":"Willemze","year":"1997","journal-title":"Blood"},{"issue":"10","key":"10.1002\/14651858.CD008946.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","article-title":"WHO-EORTC classification for cutaneous lymphomas","volume":"105","author":"Willemze","year":"2005","journal-title":"Blood"},{"issue":"8","key":"10.1002\/14651858.CD008946.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.bbmt.2009.04.017","article-title":"A meta-analysis of patients receiving allogeneic or autologous hematopoietic stem cell transplant in mycosis fungoides and Sezary syndrome","volume":"15","author":"Wu","year":"2009","journal-title":"Biology of Blood & Marrow Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD008946.pub2-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S0190-9622(99)70491-3","article-title":"Prognosis in cutaneous T-cell lymphoma by skin stage: Long-term survival in 489 patients","volume":"40","author":"Zackheim","year":"1999","journal-title":"Journal of the American Academy of Dermatology"}],"updated-by":[{"DOI":"10.1002\/14651858.cd008946.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2020,7,7]],"date-time":"2020-07-07T00:00:00Z","timestamp":1594080000000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD008946.pub2\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,28]],"date-time":"2024-04-28T18:50:29Z","timestamp":1714330229000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD008946.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Skin Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2012,9,12]]},"references-count":116,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd008946.pub2","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717958422.793464038","asserted-by":"object"}]},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9,12]]}}}